ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2024
[Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation].
Y Xu, J Zhang, S L Xue, M Miao, Y Wang, S N Chen, H Y Qiu, D P Wu
Abstract readEnglish Abstract
In one paragraphArticle in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Y XuThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
J ZhangThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
S L XueThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
M MiaoThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
Y WangThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
S N ChenThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
H Y QiuThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
D P WuThe First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China.
Funding
Jiangsu Province Elderly Health Research Project LKM2023015National Key R&D Program of China 2022YFC2502700National Natural Science Foundation of China 82020108003Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) Jiangsu Provincial Medical Innovation Center CXZX202201The Natural Science Foundation of Jiangsu Province BK20201168
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Aniline Compoundsfms-Like Tyrosine Kinase 3Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteMutationPyrazinesAdolescentAdultAgedDisease-Free SurvivalFemaleHumansMaleMiddle AgedRemission InductionRetrospective StudiesAniline CompoundsFLT3 protein, humanfms-Like Tyrosine Kinase 3gilteritinibPyrazinesAllogeneic hematopoietic stem cell transplantationFLT3-ITD mutationGilteritinibLeukemia, myeloid, acuteRefractoryRelapse
Identifiers
PMID38951063
PMCPMC11168009
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390